Marsh McLennan and Its Businesses Will Brand as Marsh
14.10.2025 13:15:00 CEST | Business Wire | Press Release
Marsh McLennan (NYSE: MMC) today announced that it will change its brand to Marsh effective January 2026, and it has created a new unit, Business and Client Services (BCS), to accelerate innovation and centralize investments in operational excellence, data, AI and analytics.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251013772875/en/
Marsh McLennan and its businesses will brand as Marsh. The new Marsh brand comes to life with a new logo – a bold design that represents the unique perspectives the Company offers.
“In an increasingly complex environment, clients are seeking advice, solutions and insights that draw on expertise from across our firm,” said John Doyle, President and CEO of Marsh McLennan. “The changes we announce today reflect the way we continue to bring our Company together to better help our clients overcome challenges and find opportunity.”
The new Marsh brand
The new Marsh brand will represent the Company’s market-leading, specialized capabilities across risk, reinsurance and capital, people and investments, and management consulting, and reflects the Company’s continued evolution to become increasingly impactful for its clients. The Company’s four businesses will adopt the Marsh brand beginning in 2027, following a transition period.
“Today, Marsh stands for excellence in risk advising and insurance broking. The new Marsh brand will also symbolize everything our company has to offer: a distinct combination of capabilities in professional services, scale and specialization for clients, enabled by cutting-edge AI and analytics,” said Mr. Doyle.
“Unifying under one brand will accelerate the impact we deliver to the marketplace and give clients even greater confidence to thrive through the power of perspective,” said John Jones, Chief Marketing and Communications Officer of Marsh McLennan.
“The new Marsh brand comes to life with a new logo – a bold design that represents the greater impact we can have with clients and the unique perspectives we offer,” said Mr. Jones.
After the transition period, Marsh and Mercer will each go to market under the new Marsh brand. Guy Carpenter will be Marsh Re. Oliver Wyman will go to market as Oliver Wyman, a Marsh business, while the operating unit Oliver Wyman Group will become Marsh Management Consulting.
The Company’s stock ticker symbol will become “MRSH” in January 2026.
Business and Client Services
BCS brings together the firm’s technology, data and operations teams under the leadership of Paul Beswick, Marsh McLennan’s Chief Information and Operations Officer. Through BCS, the Company will create a data and technology ecosystem that harnesses AI and other technologies to enhance client outcomes across its businesses while delivering operational excellence and efficiency.
“The rapid development of AI, and the insights it can derive from our data, will help unlock new opportunities for our clients and colleagues,” said Mr. Beswick. “By harnessing this powerful tool to simplify operations and elevate service quality, we will drive innovation and deliver efficiencies to reinvest in client value and growth.”
“With the changes announced today, our brand will embody the greater value we can create for all our stakeholders, while BCS will drive enhanced client service. Both initiatives reflect our steadfast commitment to delivering meaningful outcomes and exceptional experiences for our clients and colleagues," said Mr. Doyle.
About Marsh McLennan
Marsh McLennan (NYSE: MMC) is a global leader in risk, strategy and people, advising clients in 130 countries across four businesses: Marsh, Guy Carpenter, Mercer and Oliver Wyman. With annual revenue of over $24 billion and more than 90,000 colleagues, Marsh McLennan helps build the confidence to thrive through the power of perspective. For more information, visit marshmclennan.com, or follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251013772875/en/
Contacts
Media Contact:
Erick Gustafson
Marsh McLennan
+1 202 263 7788
erick.gustafson@mmc.com
Investor Contact:
Jay Gelb
Marsh McLennan
+1 212 345 1569
jay.gelb@mmc.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press Release
Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, showed the study met its dual primary endpoints of overall survival (OS) and progression-free survival (PFS). Gastric cancer is a leading cause of cancer-related death worldwide, and outcomes are particularly poor once the disease is advanced.1 Because treatment options are limited for people whose cancer continues to progress after multiple therapies, there is a significant need for new targeted therapies.2 CLDN18.2, a protein found at abnormally high levels on the surface of certain cancer cells, has emerged as a key biomarke
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press Release
Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland required for equivalent yields and logistical carbon. Digital Reef CEO Piers Slater stated "Digital Reef embrace data centre growth and environment
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press Release
SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results (Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5% 6% Income before taxes - GAAP basis $1,019 $1,018 $1,000 0% 2% Income before taxes margin - GAAP basis 10.8% 11.4% 11.2% -57 bps -42 bps Net income attributable to SLB - GAAP basis $735 $786 $739 -6% -1% Diluted EPS - GAAP basis $0.49 $0.52 $0.50 -6% -2% Adjusted EBITDA* $2,067 $1,899 $2,061 9% - Adjusted EBITDA margin* 21.9% 21.2% 23.1% 71 bps -121 bps Pretax segment operating income* $1,576 $1,404 $1,626 12% -3% Pretax segment operating margin* 16.7% 15.6% 18.2% 104 bps -153 bps Net income attributable to SLB, excluding charges & credits* $962 $833 $1,027
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom